Account wins

Share this article:

MedAccess, a division of Access Communications, has been named agency of record for Stiefel Laboratories, brought on board to help with the launch of skin-care products, Extina and RevalèSkin. Extina was recently FDA approved for the topical treatment of seborrheric dermatitis, a chronic, recurrent skin condition that affects about five percent of the country's population. Extina is administered via VersaFoam HF, which studies show offers consistent skin permeation, drug distribution and drug delivery. This easy-to-use drug also absorbs quickly and is non-drying with no residue. RevalèSkin is the first and only professional anti-aging skin care line formulated with 1% CoffeeBerry, a natural super-antioxidant.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.